FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890024596> ?p ?o ?g. }

• W2890024596 endingPage "3677" @default.
• W2890024596 startingPage "3669" @default.
• W2890024596 abstract "The objective of this study was to evaluate the efficacy of a combination of gemcitabine and docetaxel (GD) as a second-line treatment for elderly patients with metastatic urothelial carcinoma (mUC).A total of 122 patients with mUC who were previously treated with platinum-based chemotherapy received second-line GD therapy from July 2010 to June 2016. This consisted of 800 mg/m2 gemcitabine and 40 mg/m2 docetaxel on days 1 and 8 in each 21-day cycle. Using pooled cumulative data, we divided patients into the following three groups based on age: <65 years (Group A), from 65 to 74 years (Group B), and ≥75 years (Group C), and then the data were retrospectively analyzed. All patients were evaluated for treatment-related toxicities and assessed at every cycle by imaging studies. Kaplan-Meier curves were used for survival and recurrence analyses. Furthermore, potential prognostic factors for progression-free survival (PFS) and overall survival (OS) were assessed via univariate and multivariate Cox regression analyses.The median follow-up period was 8.2 months (range: 2.1-100). The median number of treatment cycles was three (range: 1-16) in Group A, three (1-15) in Group B, and two (1-11) in Group C. The objective response rate was not significantly different between the three groups. In addition, PFS and OS from the start of second-line GD therapy were also not significantly different. According to univariate and multivariate analyses of the second-line GD-treated cohort, a good performance status was the only prognostic factor for PFS and OS. In Group C, myelosuppression including predominant neutropenia and anemia, fatigue, and nausea were the main common adverse events. However, the incidence of neutropenia and a reduction in platelets were not significantly different between the three groups. Treatment-related deaths did not occur in this study.In this study, GD combination therapy as a second-line treatment for mUC resulted in favorable tumor responses and few treatment-related toxicities, even among elderly patients." @default.
• W2890024596 created "2018-09-27" @default.
• W2890024596 creator A5021695536 @default.
• W2890024596 creator A5026753886 @default.
• W2890024596 creator A5047575153 @default.
• W2890024596 creator A5057737749 @default.
• W2890024596 creator A5065853321 @default.
• W2890024596 creator A5066401468 @default.
• W2890024596 creator A5067957872 @default.
• W2890024596 creator A5070315642 @default.
• W2890024596 creator A5073925535 @default.
• W2890024596 creator A5078136909 @default.
• W2890024596 creator A5086194342 @default.
• W2890024596 creator A5091003441 @default.
• W2890024596 date "2018-09-01" @default.
• W2890024596 modified "2023-10-15" @default.
• W2890024596 title "Gemcitabine and docetaxel as second-line chemotherapy in elderly patients with metastatic urothelial carcinoma: a retrospective analysis" @default.
• W2890024596 cites W1522557416 @default.
• W2890024596 cites W1542337415 @default.
• W2890024596 cites W1718323541 @default.
• W2890024596 cites W1966672503 @default.
• W2890024596 cites W1968626722 @default.
• W2890024596 cites W1978502285 @default.
• W2890024596 cites W1982719862 @default.
• W2890024596 cites W1991893506 @default.
• W2890024596 cites W1999411449 @default.
• W2890024596 cites W2000445173 @default.
• W2890024596 cites W2001284779 @default.
• W2890024596 cites W2019607817 @default.
• W2890024596 cites W2032675047 @default.
• W2890024596 cites W2033916414 @default.
• W2890024596 cites W2047993673 @default.
• W2890024596 cites W2049701654 @default.
• W2890024596 cites W2062668422 @default.
• W2890024596 cites W2101562875 @default.
• W2890024596 cites W2102116016 @default.
• W2890024596 cites W2103257412 @default.
• W2890024596 cites W2114532259 @default.
• W2890024596 cites W2131423565 @default.
• W2890024596 cites W2149386818 @default.
• W2890024596 cites W2157244703 @default.
• W2890024596 cites W2295876927 @default.
• W2890024596 cites W2562774782 @default.
• W2890024596 cites W2582671354 @default.
• W2890024596 cites W2588916311 @default.
• W2890024596 cites W2738200477 @default.
• W2890024596 cites W2745624257 @default.
• W2890024596 cites W2768724849 @default.
• W2890024596 cites W2771737095 @default.
• W2890024596 cites W2777192533 @default.
• W2890024596 cites W2781097747 @default.
• W2890024596 cites W4211117646 @default.
• W2890024596 cites W67889411 @default.
• W2890024596 cites W864220573 @default.
• W2890024596 doi "https://doi.org/10.2147/cmar.s172913" @default.
• W2890024596 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6152597" @default.
• W2890024596 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30271215" @default.
• W2890024596 hasPublicationYear "2018" @default.
• W2890024596 type Work @default.
• W2890024596 sameAs 2890024596 @default.
• W2890024596 citedByCount "2" @default.
• W2890024596 countsByYear W28900245962019 @default.
• W2890024596 countsByYear W28900245962020 @default.
• W2890024596 crossrefType "journal-article" @default.
• W2890024596 hasAuthorship W2890024596A5021695536 @default.
• W2890024596 hasAuthorship W2890024596A5026753886 @default.
• W2890024596 hasAuthorship W2890024596A5047575153 @default.
• W2890024596 hasAuthorship W2890024596A5057737749 @default.
• W2890024596 hasAuthorship W2890024596A5065853321 @default.
• W2890024596 hasAuthorship W2890024596A5066401468 @default.
• W2890024596 hasAuthorship W2890024596A5067957872 @default.
• W2890024596 hasAuthorship W2890024596A5070315642 @default.
• W2890024596 hasAuthorship W2890024596A5073925535 @default.
• W2890024596 hasAuthorship W2890024596A5078136909 @default.
• W2890024596 hasAuthorship W2890024596A5086194342 @default.
• W2890024596 hasAuthorship W2890024596A5091003441 @default.
• W2890024596 hasBestOaLocation W28900245961 @default.
• W2890024596 hasConcept C121608353 @default.
• W2890024596 hasConcept C126322002 @default.
• W2890024596 hasConcept C126894567 @default.
• W2890024596 hasConcept C143998085 @default.
• W2890024596 hasConcept C144301174 @default.
• W2890024596 hasConcept C167135981 @default.
• W2890024596 hasConcept C2776694085 @default.
• W2890024596 hasConcept C2780258809 @default.
• W2890024596 hasConcept C2780352672 @default.
• W2890024596 hasConcept C2781190966 @default.
• W2890024596 hasConcept C2911057145 @default.
• W2890024596 hasConcept C3019882237 @default.
• W2890024596 hasConcept C38180746 @default.
• W2890024596 hasConcept C50382708 @default.
• W2890024596 hasConcept C71924100 @default.
• W2890024596 hasConceptScore W2890024596C121608353 @default.
• W2890024596 hasConceptScore W2890024596C126322002 @default.
• W2890024596 hasConceptScore W2890024596C126894567 @default.
• W2890024596 hasConceptScore W2890024596C143998085 @default.
• W2890024596 hasConceptScore W2890024596C144301174 @default.
• W2890024596 hasConceptScore W2890024596C167135981 @default.

• next